Co-Diagnostics Advances Mosquito Surveillance Amid Rising Dengue Cases in Florida

As the state of Florida experiences a concerning increase in dengue fever cases, Co-Diagnostics, Inc. (Nasdaq: CODX), a leader in molecular diagnostics, is taking strides to enhance public health surveillance. The company has successfully completed the installation of two new Vector Smart® mosquito surveillance laboratories in Florida, with plans for further installations in Indiana.

Rising Dengue Cases

According to the Florida Department of Health, the current season has seen a startling rise in locally acquired dengue cases, with 73 reported across five counties. Additionally, 14 pools of dengue-positive mosquitoes have been identified in the area. These statistics underscore the urgent need for decentralized molecular monitoring to facilitate rapid response and mitigation strategies against such mosquito-borne diseases.

Vector Smart Expansion

Co-Diagnostics' Vector Smart system is designed to provide local mosquito abatement districts with rapid PCR (Polymerase Chain Reaction) data that can significantly improve public health decision-making. Currently, the Vector Smart network serves 21 U.S. states, including seven districts in Florida, allowing for timely responses to outbreaks.

Dwight Egan, CEO of Co-Diagnostics, emphasized the importance of decentralized surveillance: “Every new Vector Smart deployment expands not just our customer footprint but a growing molecular monitoring network that enables public health agencies to generate faster, local insights into mosquito-borne disease activity. As vector-borne diseases emerge in new regions, decentralized PCR surveillance is becoming increasingly critical to public health infrastructure.”

Scalable and Flexible Platform

Co-Diagnostics designed the Vector Smart platform to be scalable and adaptable, allowing laboratories to address multiple mosquito-borne pathogens as surveillance needs evolve. This flexibility aims to reinforce the long-term value of the system while fostering growth in demand for recurring assays as the user base expands.

Commitment to Public Health

The recent laboratory deployments mark a significant milestone in Co-Diagnostics' expansion efforts, which were first announced in June 2026. This initiative not only strengthens the company's surveillance network but also follows the launch of its first international Vector Smart deployment and its continuous engagement with third-party evaluations.

The platform was recently independently evaluated by a state public health laboratory, adding credibility to its capabilities and increasing its appeal for broader adoption in mosquito surveillance and public health programs.

About Co-Diagnostics

Co-Diagnostics, Inc. is a Utah-based molecular diagnostics company focused on developing and marketing cutting-edge diagnostic technologies. Their proprietary systems leverage the detection of nucleic acid molecules to create state-of-the-art diagnostic tests, driving innovative solutions in an ever-evolving healthcare landscape.

In summary, the innovative work by Co-Diagnostics in launching the new Vector Smart installations highlights their commitment to combating the rise of dengue fever in Florida. Through enhancing local surveillance capabilities, the company aims to better equip public health officials in their fight against mosquito-borne diseases. As the landscape of infectious diseases continues to change, proactive measures like those taken by Co-Diagnostics will be essential in safeguarding community health and wellbeing.